Targets › ASL
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Sep 2028.
Catalyzes the reversible cleavage of L-argininosuccinate to fumarate and L-arginine, an intermediate step reaction in the urea cycle mostly providing for hepatic nitrogen detoxification into excretable urea as well as de novo L-arginine synthesis in nonhepatic tissues. Essential regulator of intracellular and extracellular L-arginine pools. (UniProt, P04424)
Open in Phaseline: the race on ASL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rebecca Ahrens-Nicklas | LNP.UCD.ABE adenine base editor (ABE) delivered by lipid nanoparticle (LNP) for urea cycle disorder ge | CPS1, OTC, ASS1, ASL, ARG1 | Phase 1 | Urea Cycle Disorders | Sep 2028 |
Urea Cycle Disorders (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.